Literature DB >> 25331444

Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years.

Simona Osella-Abate1, Simone Ribero, Martina Sanlorenzo, Milena Maria Maule, Lorenzo Richiardi, Franco Merletti, Carlo Tomasini, Elena Marra, Giuseppe Macripò, Maria Teresa Fierro, Pietro Quaglino.   

Abstract

In many centers, Stage I-II melanoma patients are considered "cured" after 10 years of disease-free survival and follow-up visits are interrupted. However, melanoma may relapse also later. We retrospectively analyzed a cohort of 1,372 Stage I-II melanoma patients who were disease-free 10 years after diagnosis. The aim of this study was to characterize patients who experienced a late recurrence and to compare them to those who remained disease-free to identify possible predictive factors. Multivariate Cox proportional-hazards regression analyses were carried out to evaluate the influence of different factors on the risk of recurrence. Seventy-seven patients out of 1,372 (5.6%) relapsed, 52 in regional sites and 25 in distant ones. The majority of patients (31 out of 52) experienced late recurrence in regional lymph nodes. Brain and lung were the most common site of single distant recurrence (24% each). Patients with multiple distant metastases showed a brain and lung involvement in, respectively, 40 and 48% of cases. A Cox proportional-hazards regression model analysis showed the independent role of age under 40 years, Breslow thickness >2 mm, and Clark Level IV/V in increasing the risk of Late Recurrence. These patients should be followed-up for longer than 10 years. The pattern of recurrence suggests that melanoma cells can be dormant preferentially in lymph nodes, brain and lung. A particular attention should be reserved to these anatomic sites during the follow-up after 10 years of disease-free.
© 2014 UICC.

Entities:  

Keywords:  dormancy; late metastases; melanoma; pattern of recurrence

Mesh:

Year:  2014        PMID: 25331444     DOI: 10.1002/ijc.29281

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Endobronchial, laryngeal and mediastinal melanoma: a rare constellation of metastatic disease.

Authors:  Grace Nabila Martinez Pena; Chuan Jiang
Journal:  BMJ Case Rep       Date:  2019-05-08

Review 2.  EMT, CTCs and CSCs in tumor relapse and drug-resistance.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Oncotarget       Date:  2015-05-10

3.  Endobronchial melanoma metastasis 40 years after the excision of the primary cutaneous tumor: A case report.

Authors:  Georgia Karpathiou; Marios Froudarakis; Vanessa Da Cruz; Fabien Forest; Maxime Sauvage; Jean Michel Vergnon; Michel Peoc'h
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas.

Authors:  Simona Osella-Abate; Elisabetta Mereu; Elisa Pellegrino; Elisa Bergaggio; Simone Ribero; Luca Bertero; Francesco Lisa; Maria Teresa Fierro; Mauro Giulio Papotti; Roberto Piva
Journal:  Oncol Lett       Date:  2018-10-09       Impact factor: 2.967

Review 5.  Signaling of Tumor-Derived sEV Impacts Melanoma Progression.

Authors:  Aneta Zebrowska; Piotr Widlak; Theresa Whiteside; Monika Pietrowska
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

6.  A 41-Year-Old Woman with a Late Cerebral Metastasis 16 Years After an Initial Diagnosis of Cutaneous Melanoma.

Authors:  Qi Yu; Yawen Ma; Tianda Feng
Journal:  Am J Case Rep       Date:  2022-03-08

7.  Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma.

Authors:  Jun S Liu; Sumati Rao
Journal:  Exp Hematol Oncol       Date:  2016-04-11

Review 8.  Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma.

Authors:  Allison L Isola; Kevinn Eddy; Suzie Chen
Journal:  Cancers (Basel)       Date:  2016-12-09       Impact factor: 6.639

9.  A Novel Signature of 23 Immunity-Related Gene Pairs Is Prognostic of Cutaneous Melanoma.

Authors:  Ya-Nan Xue; Yi-Nan Xue; Zheng-Cai Wang; Yong-Zhen Mo; Pin-Yan Wang; Wei-Qiang Tan
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

10.  Late Metastatic Melanoma after 25 Years: A Case Report and a Brief Literature Review.

Authors:  Elena Pescarini; Gabriela Spanikova; Zacharia Mbaidjol; Eleonora De Antoni; Vincenzo Vindigni; Franco Bassetto
Journal:  Case Rep Surg       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.